438 reports of this reaction
1.5% of all ROTIGOTINE reports
#14 most reported adverse reaction
APPLICATION SITE PRURITUS is the #14 most commonly reported adverse reaction for ROTIGOTINE, manufactured by UCB, Inc.. There are 438 FDA adverse event reports linking ROTIGOTINE to APPLICATION SITE PRURITUS. This represents approximately 1.5% of all 28,260 adverse event reports for this drug.
Patients taking ROTIGOTINE who experience application site pruritus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE PRURITUS is a less commonly reported adverse event for ROTIGOTINE, but still significant enough to appear in the safety profile.
In addition to application site pruritus, the following adverse reactions have been reported for ROTIGOTINE:
The following drugs have also been linked to application site pruritus in FDA adverse event reports:
APPLICATION SITE PRURITUS has been reported as an adverse event in 438 FDA reports for ROTIGOTINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE PRURITUS accounts for approximately 1.5% of all adverse event reports for ROTIGOTINE, making it a notable side effect.
If you experience application site pruritus while taking ROTIGOTINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.